INVALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒═══════════════════════════════════════════════════╤═══════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                 │ CHIA Criteria                                     │   Score │
╞═══════════════════════════════════════════════════╪═══════════════════════════════════════════════════╪═════════╡
│ All patients referred to a participating research │ All patients referred to a participating research │     100 │
│ centre with suspicion of or confirmed endometrial │ centre with suspicion of or confirmed endometrial │         │
│ cancer                                            │ cancer                                            │         │
├───────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Patients who will not get surgical treatment for  │ Patients who will not get surgical treatment for  │     100 │
│ their endometrial cancer                          │ their endometrial cancer                          │         │
├───────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Patients with endometrial or epithelial ovarian   │ Patients with endometrial or epithelial ovarian   │     100 │
│ cancer who following routine clinical guidelines  │ cancer who following routine clinical guidelines  │         │
│ are offered weekly taxane (paclitaxel) treatment. │ are offered weekly taxane (paclitaxel) treatment. │         │
│ This will often be a third or fourth line         │ This will often be a third or fourth line         │         │
│ treatment, i.e. patients with advanced disease    │ treatment, i.e. patients with advanced disease    │         │
├───────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Technical possibility to obtain a new tissue      │ Technical possibility to obtain a new tissue      │     100 │
│ biopsy to determine stathmin level in the tumour  │ biopsy to determine stathmin level in the tumour  │         │
│ recurrence                                        │ recurrence                                        │         │
├───────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Patients not suffering from endometrial or        │ Patients not suffering from endometrial or        │     100 │
│ epithelial ovarian cancer                         │ epithelial ovarian cancer                         │         │
├───────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Patients who do not agree to the proposed         │ Patients who do not agree to the proposed         │     100 │
│ treatment or will receive (part of) the treatment │ treatment or will receive (part of) the treatment │         │
│ in a non-participating centre                     │ in a non-participating centre                     │         │
├───────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Patients who cannot or do not want to give        │ Patients who cannot or do not want to give        │     100 │
│ informed consent (including language barriers)    │ informed consent (including language barriers)    │         │
├───────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Patients who will or cannot give informed consent │ Patients who cannot or do not want to give        │      86 │
│ (including language barriers)                     │ informed consent (including language barriers)    │         │
╘═══════════════════════════════════════════════════╧═══════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒═════════════════════════════════════════════╤══════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                           │ CHIA Criteria                                    │   Score │
╞═════════════════════════════════════════════╪══════════════════════════════════════════════════╪═════════╡
│ part 1                                      │ Patients not suffering from endometrial or       │      11 │
│                                             │ epithelial ovarian cancer                        │         │
├─────────────────────────────────────────────┼──────────────────────────────────────────────────┼─────────┤
│ part 1                                      │ Patients not suffering from endometrial or       │      11 │
│                                             │ epithelial ovarian cancer                        │         │
├─────────────────────────────────────────────┼──────────────────────────────────────────────────┼─────────┤
│ Must be FEMALE                              │ Patients not suffering from endometrial or       │      12 │
│                                             │ epithelial ovarian cancer                        │         │
├─────────────────────────────────────────────┼──────────────────────────────────────────────────┼─────────┤
│ Must have maximum age of 95 Years           │ Patients who will not get surgical treatment for │      30 │
│                                             │ their endometrial cancer                         │         │
├─────────────────────────────────────────────┼──────────────────────────────────────────────────┼─────────┤
│ Must have minimum age of 18 Years           │ Patients who will not get surgical treatment for │      32 │
│                                             │ their endometrial cancer                         │         │
├─────────────────────────────────────────────┼──────────────────────────────────────────────────┼─────────┤
│ Exclusion criteria part 2                   │ Patients not suffering from endometrial or       │      32 │
│                                             │ epithelial ovarian cancer                        │         │
├─────────────────────────────────────────────┼──────────────────────────────────────────────────┼─────────┤
│ Inclusion criteria part 2                   │ Patients not suffering from endometrial or       │      34 │
│                                             │ epithelial ovarian cancer                        │         │
├─────────────────────────────────────────────┼──────────────────────────────────────────────────┼─────────┤
│ Patients \<18 years of age                  │ Patients not suffering from endometrial or       │      38 │
│                                             │ epithelial ovarian cancer                        │         │
├─────────────────────────────────────────────┼──────────────────────────────────────────────────┼─────────┤
│ Patients \<18 years of age                  │ Patients not suffering from endometrial or       │      38 │
│                                             │ epithelial ovarian cancer                        │         │
├─────────────────────────────────────────────┼──────────────────────────────────────────────────┼─────────┤
│ Patients who do not have endometrial cancer │ Patients who will not get surgical treatment for │      67 │
│                                             │ their endometrial cancer                         │         │
╘═════════════════════════════════════════════╧══════════════════════════════════════════════════╧═════════╛

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 77
Average Levenshtein Ratio of individual lines: 60.611111111111114
OverAll Ratio: 68.80555555555556
